MedTrace Logo

Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function

NCT01372826 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2014-10-15

No results posted yet for this study

Summary

This study will be assessing the pharmacokinetics of NKTR-118 in subjects with renal impairment compared to that in subjects with normal renal function.

Conditions

  • Renal Impairment

Interventions

DRUG

NKTR118 Group1

Oral dose, 25 mg

DRUG

NKTR118 Group 2

Oral dose, 25 mg

DRUG

NKTR118 Group3

Oral dose, 25 mg

DRUG

NKTR118

Oral dose, 25 mg

Sponsors & Collaborators

Principal Investigators

  • Mark Sostek, MD · AstraZeneca

  • Thomas Marbury, MD · Orlando Clinical Research Center US

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2011-10-31
Completion
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01372826 on ClinicalTrials.gov